Jie Yang

Jie Yang

Auto-generated profile, based on publicly available information

Jie Yang

Department of Pathology, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in Nature
Verified
Journal Article
Open access
PDF file
JYJie Yang
Jie Yang
YYYumi Yamashita-Kanemaru
Yumi Yamashita-Kanemaru
BMBenjamin I. Morris
Benjamin I. Morris
ACAnnalisa Contursi
Annalisa Contursi
DTDaniel Trajkovski
Daniel Trajkovski
RRRahul Roychoudhuri
Rahul Roychoudhuri
Metastasis is the spread of cancer cells from primary tumours to distant organs and is the cause of 90% of cancer deaths globally1,2. Metastasizing cancer cells are uniquely vulnerable to immune attack, as they are initially deprived of the immunosuppressive microenvironment found within established tumours3. There is interest in therapeutically exploiting this immune vulnerability to prevent recurrence in patients with early cancer at risk of metastasis. Here we show that inhibitors of cyclooxygenase 1 (COX-1), including aspirin, enhance immunity to cancer metastasis by releasing T cells from suppression by platelet-derived thromboxane A2 (TXA2). TXA2 acts on T cells to trigger an immunosuppressive pathway that is dependent on the guanine exchange factor ARHGEF1, suppressing T cell receptor-driven kinase signalling, proliferation and effector functions. T cell-specific conditional deletion of Arhgef1 in mice increases T cell activation at the metastatic site, provoking immune-mediated rejection of lung and liver metastases. Consequently, restricting the availability of TXA2 using aspirin, selective COX-1 inhibitors or platelet-specific deletion of COX-1 reduces the rate of metastasis in a manner that is dependent on T cell-intrinsic expression of ARHGEF1 and signalling by TXA2 in vivo. These findings reveal a novel immunosuppressive pathway that limits T cell immunity to cancer metastasis, providing mechanistic insights into the anti-metastatic activity of aspirin and paving the way for more effective anti-metastatic immunotherapies.

16 December 2022 in Science Immunology
Verified
Journal Article
Closed access
SGSilvia Gaggero
Silvia Gaggero
JMJonathan Martinez-Fabregas
Jonathan Martinez-Fabregas
ACAdeline Cozzani
Adeline Cozzani
PFPaul K. Fyfe
Paul K. Fyfe
MLMalo Leprohon
Malo Leprohon
SMSuman Mitra
Suman Mitra
Cytokines interact with their receptors in the extracellular space to control immune responses. How the physicochemical properties of the extracellular space influence cytokine signaling is incompletely elucidated. Here, we show that the activity of interleukin-2 (IL-2), a cytokine critical to T cell immunity, is profoundly affected by pH, limiting IL-2 signaling within the acidic environment of tumors. Generation of lactic acid by tumors limits STAT5 activation, effector differentiation, and antitumor immunity by CD8 + T cells and renders high-dose IL-2 therapy poorly effective. Directed evolution enabled selection of a pH-selective IL-2 mutein (Switch-2). Switch-2 binds the IL-2 receptor subunit IL-2Rα with higher affinity, triggers STAT5 activation, and drives CD8 + T cell effector function more potently at acidic pH than at neutral pH. Consequently, high-dose Switch-2 therapy induces potent immune activation and tumor rejection with reduced on-target toxicity in normal tissues. Last, we show that sensitivity to pH is a generalizable property of a diverse range of cytokines with broad relevance to immunity and immunotherapy in healthy and diseased tissues.

9 June 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
FGFrancis M. Grant
Francis M. Grant
JYJie Yang
Jie Yang
RNRabab Nasrallah
Rabab Nasrallah
JCJames Clarke
James Clarke
FSFiras Sadiyah
Firas Sadiyah
RRRahul Roychoudhuri
Rahul Roychoudhuri
Regulatory T (Treg) cell populations are composed of functionally quiescent resting Treg (rTreg) cells which differentiate into activated Treg (aTreg) cells upon antigen stimulation. How rTreg cells remain quiescent despite chronic exposure to cognate self- and foreign antigens is unclear. The transcription factor BACH2 is critical for early Treg lineage specification, but its function following lineage commitment is unresolved. Here, we show that BACH2 is repurposed following Treg lineage commitment and promotes the quiescence and long-term maintenance of rTreg cells. Bach2 is highly expressed in rTreg cells but is down-regulated in aTreg cells and during inflammation. In rTreg cells, BACH2 binds to enhancers of genes involved in aTreg differentiation and represses their TCR-driven induction by competing with AP-1 factors for DNA binding. This function promotes rTreg cell quiescence and long-term maintenance and is required for immune homeostasis and durable immunosuppression in cancer. Thus, BACH2 supports a “division of labor” between quiescent rTreg cells and their activated progeny in Treg maintenance and function, respectively.

13 May 2020 in Nature
Verified
Journal Article
Closed access
PDF file
RNRabab Nasrallah
Rabab Nasrallah
CICharlotte J. Imianowski
Charlotte J. Imianowski
LBLara Bossini-Castillo
Lara Bossini-Castillo
FGFrancis M. Grant
Francis M. Grant
MDMikail Dogan
Mikail Dogan
RRRahul Roychoudhuri
Rahul Roychoudhuri

22 February 2018 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JYJie Yang
Jie Yang
FCFerry Cornelissen
Ferry Cornelissen
NPNatalie Papazian
Natalie Papazian
Rogier ReijmersRogier Reijmers
Rogier Reijmers
MLMiriam Llorian
Miriam Llorian
BSBenedict Seddon
Benedict Seddon
IL-7 is essential for the development and homeostasis of T and B lymphocytes and is critical for neonatal lymph node organogenesis because Il7−/− mice lack normal lymph nodes. Whether IL-7 is a continued requirement for normal lymph node structure and function is unknown. To address this, we ablated IL-7 function in normal adult hosts. Either inducible Il7 gene deletion or IL-7R blockade in adults resulted in a rapid loss of lymph node cellularity and a corresponding defect in lymphocyte entry into lymph nodes. Although stromal and dendritic cell components of lymph nodes were present in normal numbers and representation, innate lymphoid cell (ILC) subpopulations were substantially decreased after IL-7 ablation. Testing lymphocyte homing in bone marrow chimeras reconstituted with Rorc−/− bone marrow confirmed that ILC3s in lymph nodes are required for normal lymphocyte homing. Collectively, our data suggest that maintenance of intact lymph nodes relies on IL-7–dependent maintenance of ILC3 cells.

15 December 2023 in Science Immunology
Verified
Journal Article
Open access
SWSarah K. Whiteside
Sarah K. Whiteside
FGFrancis M. Grant
Francis M. Grant
GAGiorgia Alvisi
Giorgia Alvisi
JCJames Clarke
James Clarke
LTLeqi Tang
Leqi Tang
RRRahul Roychoudhuri
Rahul Roychoudhuri
Regulatory T (T reg ) cells contribute to immune homeostasis but suppress immune responses to cancer. Strategies to disrupt T reg cell–mediated cancer immunosuppression have been met with limited clinical success, but the underlying mechanisms for treatment failure are poorly understood. By modeling T reg cell–targeted immunotherapy in mice, we find that CD4 + Foxp3 − conventional T (T conv ) cells acquire suppressive function upon depletion of Foxp3 + T reg cells, limiting therapeutic efficacy. Foxp3 − T conv cells within tumors adopt a T reg cell–like transcriptional profile upon ablation of T reg cells and acquire the ability to suppress T cell activation and proliferation ex vivo. Suppressive activity is enriched among CD4 + T conv cells marked by expression of C-C motif receptor 8 (CCR8), which are found in mouse and human tumors. Upon T reg cell depletion, CCR8 + T conv cells undergo systemic and intratumoral activation and expansion, and mediate IL-10–dependent suppression of antitumor immunity. Consequently, conditional deletion of Il10 within T cells augments antitumor immunity upon T reg cell depletion in mice, and antibody blockade of IL-10 signaling synergizes with T reg cell depletion to overcome treatment resistance. These findings reveal a secondary layer of immunosuppression by T conv cells released upon therapeutic T reg cell depletion and suggest that broader consideration of suppressive function within the T cell lineage is required for development of effective T reg cell–targeted therapies.